欢迎来到CSNpharm!产品仅用于科研!

400-920-2911 sales@csnpharm.cn

0

Bcr-Abl

Bcr-Abl

货号 产品名 CAS号 信息
CSN15826 ZM306416 690206-97-4 ZM-306416 is an inhibitor of VEGFR (Flk-1 or KDR) and Flt with IC50 of 100 nM and 2 μM. It also shows inhibition activity against Src and Abl with IC50 values of 0.33μM and 1.3μM, respectively.
CSN22517 Target Protein-binding Moiety 8 910297-51-7 PROTAC Bcr-Abl-binding moiety 1 is a Dasatinib-based warhead ligand for conjugation reactions of PROTAC targeting on Bcr-Abl.
CSN16663 NVP-BHG712 940310-85-0 NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition and also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
CSN12740 Lyn-IN-1 887650-05-7 Lyn-IN-1 is a potent and selective dual Bcr-Abl/Lyn inhibitor with potential antineoplastic activity, it is an orally bioavailable 2-phenylaminopyrimidine derivative.
CSN12398 GNF-5 778277-15-9 GNF-5 is a selective non-ATP competitive inhibitor of Bcr-Abl with IC50 of 220 nM, it's an analogue of GNF-2 with improved pharmacokinetic properties.
CSN25549 GMB-475 2490599-18-1 GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 reduced viability and increased apoptosis in primary CML CD34+ cells, with no effect on healthy CD34+ cells at identical concentrations.
CSN16096 DPH 484049-04-9 DPH is a potent cell permeable c-Abl activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation.
CSN21248 BCR-ABL-IN-1 188260-50-6 BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia.
CSN18365 AST-487 630124-46-8 AST-487 is a RET kinase inhibitor with IC50 of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits Flt-3 with IC50 of 520 nM. AST487 also inhibits RET,KDR,c-KIT,and c-ABL kinase with IC50 values below 1 μM.
<< PREV 1 2 NEXT >>
联系
我们